Evidence map›Paper›PMID 42658040›Full record

ArticleThe American Journal of dermatopathology2026

Hidden Malignancy: Predominantly InSitu Porocarcinoma Arising in a Poroma.

Fabio Del Carro, Giovanni Evalli, Giovanni Fellegara

Abstract readCase Reports
In one paragraph

Article in The American Journal of dermatopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fabio Del CarroSchool of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.ORCID 0009-0008-0355-1736
Giovanni EvalliCentro Salute Colleoni, Castano Primo, Italy.
Giovanni FellegaraPathology Unit, Centro Diagnostico Italiano (CDI), Milan, Italy; and.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractPorocarcinoma is a rare malignant adnexal tumor which can originate either de novo or-much more rarely-from a preexisting eccrine poroma. Given its aggressive clinical behavior, a timely diagnosis is essential for optimal patient's management. We report the case of a 79-year-old woman presenting with a well-circumscribed exophytic mass located on her right calcaneal region, which had been present for 2 years but had recently shown progressive enlargement. An excisional diagnostic biopsy was performed, and histopathological examination showed a poroid lesion with no malignant features. A diagnosis of eccrine poroma was then considered. However, deeper sections revealed a focal intraepidermal proliferation of markedly atypical cells and a small intradermal nest suggestive of early dermal invasion. The atypical population was characterized by overexpression of both p53 and p16, an increased ki-67 proliferation index, and preserved mismatch repair proteins. The diagnosis was then changed into a predominantly in situ , focally invasive porocarcinoma arising in an eccrine poroma. The patient underwent electrocautery of the wound margins and an echographic examination of pelvic nodes-which were negative for metastases-and was free of recurrence at a 6-month follow-up. This case provides evidence that benign-looking eccrine poromas may harbor microscopic foci of malignant transformation, thus emphasizing the need for a careful and thorough histopathological evaluation of these lesions.

Indexed as

Eccrine PorocarcinomaNeoplasms, Multiple PrimaryPoromaSweat Gland NeoplasmsAgedBiomarkers, TumorFemaleHumansNon-Melanoma Skin NeoplasmsBiomarkers, Tumorcutaneous adnexal tumorsmismatch repair proteinsporocarcinomaporomaskin cancer

Identifiers

PMID42658040
PMCPMC13585160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.